213
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Jazz Pharmaceuticals's recently active trials. Comparator arms are excluded.
- Sativex15 trials
- Zanidatamab8 trials
- Sativex®8 trials
- GW-1000-027 trials
- Nabiximols6 trials
- Dordaviprone (ONC201)5 trials
Upcoming readouts
Next primary completion dates among Jazz Pharmaceuticals's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Dec 2026A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPhase 2
- Dec 2027XYRISE: A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants W…Phase 3
- Jan 2028EmpowHER 208: A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With…Phase 2
- Jan 2028A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With E…Phase 2
- Apr 2028A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination Wit…Phase 3
- Jun 2028ACTION: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)Phase 3
Top therapeutic areas
Conditions studied most often across Jazz Pharmaceuticals's recently active trials.
- Pain14 trials
- Multiple Sclerosis13 trials
- Narcolepsy6 trials
- Spasticity6 trials
- Advanced Cancer4 trials
- Acute Myeloid Leukemia4 trials
Jazz Pharmaceuticals pipeline by phase
The main study drugs across 22 active trials Jazz Pharmaceuticals leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 34 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Zanidatamab | 6 | 4 | Sept 2026 est. | NCT06435429 · NCT06282575 · NCT05152147 |
| CBD-OS | 2 | 1 | Nov 2027 est. | NCT07723976 · NCT07233239 |
| Dordaviprone (ONC201) | 1 | 1 | Jun 2028 est. | NCT05580562 |
| Xywav | 1 | 1 | Dec 2027 est. | NCT07625280 |
Phase 24 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Lurbinectedin | 2 | 2 | Jan 2028 est. | NCT07459634 · NCT05734066 |
| ONC206 | 2 | 2 | Dec 2028 est. | NCT07282587 · NCT04541082 |
| JZP3507 | 1 | 1 | Oct 2028 est. | NCT07533942 |
| JZP926 capsule | 1 | — | Aug 2028 est. | NCT07723963 |
Phase 14 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| JZP047 | 1 | 1 | — | NCT07377539 |
| JZP269 | 1 | — | Feb 2027 est. | NCT07813663 |
| JZP815 | 1 | — | Apr 2028 est. | NCT05557045 |
| JZP898 | 1 | 1 | Nov 2027 est. | NCT06108050 |
Phase 42 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Cannabidiol | 1 | — | Aug 2027 est. | NCT05044819 |
| Cannabidiol Oral Solution | 1 | — | Dec 2028 est. | NCT07728097 |
Derived from 22 active trials Jazz Pharmaceuticals leads; 22 name an intervention, folding into 14 phased drugs. This is ComplyRx's reading of the registry, not Jazz Pharmaceuticals's own pipeline disclosure.
Jazz Pharmaceuticals trials
The 50 most significant of Jazz Pharmaceuticals's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| HERIZON-GEA-01A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersNCT05152147Zanidatamab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 920 est. | 30 Sept 2026 |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Zanidatamab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 200 est. | 31 Dec 2026 |
| EpiTALYEpidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALYNCT05485831Epidiolex 100 mg/mL Oral Solution | — | Not yet scored | OngoingActive, not recruiting | 111 est. | Feb 2027 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female ParticipantsNCT07813663JZP269 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 188 est. | 27 Feb 2027 |
| Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral SolutionNCT05044819Cannabidiol | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 154 est. | 1 Aug 2027 |
| A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset SeizuresNCT07233239CBD-OS | Phase 1 | Locked · track to reveal | OngoingRecruiting | 100 est. | 29 Nov 2027 |
| JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid TumorsNCT06108050JZP898 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 177 est. | 30 Nov 2027 |
| XYRISEA Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IHNCT07625280Xywav | Phase 3 | Not yet scored | OngoingRecruiting | 120 est. | 23 Dec 2027 |
| EmpowHER 208A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381Zanidatamab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 125 est. | 1 Jan 2028 |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing SarcomaNCT05734066Lurbinectedin | Phase 1 | Locked · track to reveal | OngoingRecruiting | 60 est. | 28 Jan 2028 |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCNCT07459634Lurbinectedin | Phase 2 | Locked · track to reveal | OngoingRecruiting | 50 est. | 31 Jan 2028 |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815NCT05557045JZP815 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 98 est. | 1 Apr 2028 |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerNCT06435429Zanidatamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 550 est. | 28 Apr 2028 |
| ACTIONONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)NCT05580562Dordaviprone (ONC201) | Phase 3 | Locked · track to reveal | OngoingRecruiting | 510 est. | Jun 2028 |
| A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic EpilepsyNCT07723963JZP926 capsule | Phase 2 | Not yet scored | OngoingNot yet recruiting | 260 est. | 1 Aug 2028 |
| A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 MeningiomaNCT07533942JZP3507 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 30 est. | 25 Oct 2028 |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerNCT06282575Zanidatamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 286 est. | 1 Dec 2028 |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and ParagangliomaNCT07282587ONC206 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 90 est. | 15 Dec 2028 |
| EpiGOALA Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGSNCT07728097Cannabidiol Oral Solution | Phase 4 | Not yet scored | OngoingNot yet recruiting | 40 est. | 28 Dec 2028 |
| A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEENCT07723976CBD-OS | Phase 3 | Not yet scored | OngoingNot yet recruiting | 120 est. | 4 Sept 2029 |
| ZOLAZanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEANCT07780968Zanidatamab | — | Not yet scored | OngoingNot yet recruiting | 300 est. | 1 Oct 2031 |
| Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During PregnancyNCT06113237Epidiolex | — | Not yet scored | OngoingRecruiting | 50 est. | 31 Aug 2033 |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsNCT04541082ONC206 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 102 est. | Jul 2026 |
| OPERALong-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life SettingNCT05772429Epidiolex | — | Not yet scored | OngoingActive, not recruiting | 158 est. | Jul 2026 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy ParticipantsNCT07377539JZP047 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 86 est. | 5 Jul 2026 |
| EpiComA Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis ComplexNCT05864846Cannabidiol Oral Solution [Epidiolex] | Phase 4 | Locked · track to reveal | Completed | 79 est. | 6 Apr 2026 |
| A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1NCT06961266JZP441 | Phase 1 | Locked · track to reveal | StoppedTerminated | 6 est. | 29 Jan 2026 |
| VYSIONVYxeoS Liposomal Italian Observational Study iN the Real PracticeNCT06143839Vyxeos liposomal | — | Not yet scored | Completed | 113 est. | 23 Oct 2025 |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerNCT03929666ZW25 (Zanidatamab) | Phase 2 | Locked · track to reveal | Completed | 74 est. | 30 Aug 2025 |
| A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing CancerNCT05027139Zanidatamab | Phase 1 | Locked · track to reveal | Completed | 52 est. | 29 Aug 2025 |
| SCLCTo Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)NCT04894591Zepzelca | — | Not yet scored | Completed | 272 est. | 4 Jun 2025 |
| A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or NarcolepsyNCT05875974JZP258 (XYWAV) | Phase 4 | Locked · track to reveal | Completed | 199 est. | 13 Mar 2025 |
| XYLOA Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With NarcolepsyNCT05869773JZP258 | Phase 4 | Locked · track to reveal | Completed | 155 est. | 25 Feb 2025 |
| Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled SeizuresNCT04485104GWP42003-P | Phase 3 | Locked · track to reveal | StoppedTerminated | 3 est. | 28 Jan 2025 |
| Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersNCT02892123ZW25 (Zanidatamab) | Phase 1 | Locked · track to reveal | Completed | 279 est. | 31 Oct 2024 |
| A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's DiseaseNCT05642442Suvecaltamide | Phase 2 | Locked · track to reveal | Completed | 169 est. | 23 Oct 2024 |
| Child and Adolescent Registry for Participants With NarcolepsyNCT04899947 | — | Not yet scored | Unknown | 500 est. | 1 Oct 2024 |
| A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)NCT05122650JZP385 | Phase 2 | Locked · track to reveal | Completed | 420 est. | 30 May 2024 |
| A JZP341 Study in Adult Participants With Advanced or Metastatic Solid TumorsNCT05631327JZP341 | Phase 1 | Locked · track to reveal | StoppedTerminated | 12 est. | 24 Apr 2024 |
| Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum DisorderNCT04745026GWP42003-P | Phase 2 | Locked · track to reveal | Completed | 103 est. | 21 Dec 2023 |
| JAZZ EMERGE201Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid TumorsNCT05126433Lurbinectedin | Phase 2 | Locked · track to reveal | StoppedTerminated | 47 est. | 20 Dec 2023 |
| A Study of JZP150 in Adults With Posttraumatic Stress DisorderNCT05178316JZP150 | Phase 2 | Locked · track to reveal | Completed | 282 est. | 5 Dec 2023 |
| A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy ParticipantsNCT05651152JZP441 | Phase 1 | Locked · track to reveal | Completed | 105 est. | 15 Nov 2023 |
| A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum DisorderNCT05733390JZP541 | Phase 2 | Locked · track to reveal | StoppedWithdrawn | 0 est. | 9 Nov 2023 |
| A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy ParticipantsNCT05720494JZP441 | Phase 1 | Locked · track to reveal | Completed | 24 est. | 29 Sept 2023 |
| Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic SeizuresNCT05288283GWP42003-P | Phase 3 | Locked · track to reveal | StoppedTerminated | 3 est. | 28 Sept 2023 |
| HERIZON-BTC-01A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract CancersNCT04466891ZW25 (Zanidatamab) | Phase 2 | Locked · track to reveal | Completed | 87 est. | 28 Jul 2023 |
| A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast CancerNCT04224272ZW25 (Zanidatamab) | Phase 2 | Locked · track to reveal | Completed | 51 est. | 28 Apr 2023 |
| Oral ONC201 in Adult Recurrent GlioblastomaNCT02525692Dordaviprone (ONC201) | Phase 2 | Locked · track to reveal | StoppedTerminated | 84 est. | 17 Apr 2023 |
| RELEASE MSS3Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple SclerosisNCT04203498Nabiximols | Phase 3 | Locked · track to reveal | StoppedTerminated | 139 est. | 10 Feb 2023 |